AARON CUNNINGHAM: Open Payments
NPI 1508190695 · PHILADELPHIA, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,175 in 38 payments from 10 companies in 2025. Trend: 2023 $137 · 2024 $64 · 2025 $1,175
Food & beverage: $1,024Education: $151
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 7 | $318 |
| Astellas Pharma US Inc | 5 | $252 |
| GlaxoSmithKline, LLC. | 8 | $142 |
| Verona Pharma, Inc. | 4 | $105 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $80 |
| United Therapeutics Corporation | 3 | $76 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $68 |
| Genentech USA, Inc. | 3 | $55 |
| Regeneron Healthcare Solutions, Inc. | 2 | $48 |
| GENZYME CORPORATION | 1 | $30 |
Products named: FASENRA, NUCALA, AIRSUPRA, Ohtuvayre, Cresemba, OFEV, DUPIXENT, Tyvaso.
Industry payments across PA — which companies pay providers there.
